The present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one compounds
as monoamine receptor modulators; compositions comprising the same; methods of
inhibiting an activity of a monoamine receptor with said compounds; methods of
treating a disease condition associated with a monoamine receptor using said compounds;
and methods for identifying a subject suitable for treatment using said compounds.
